Dacarbazine citrate  (Synonyms: Imidazole Carboxamide citrate)

Dacarbazine citrate is a cell cycle nonspecific antineoplastic alkylating agent. Dacarbazine citrate inhibits T and B lymphoblastic response, with IC₅₀ values of 50 and 10 μg/mL, respectively. Dacarbazine Citrate can be used for the research of apoptosis and various cancers such as metastatic malignant melanoma^[1][2].

Dacarbazine citrate has less pronounced inhibition of mitogenesis with IC₅₀ values of 50 and 10 μg/mL for T and B cells, respectively^[2].
Dacarbazine citrate (30 μM, 0-14 min) evokes a concentration-dependent calcium response in hTRPA1-HEK293 cells with an EC₅₀ value of 23 μM and selectively activates the human TRPA1 channel^[3].
Dacarbazine citrate (100-10,000 μM, 24 h) has cytotoxic action on B16-F10 melanoma cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Dacarbazine citrate (1 mg/kg, i.p.) evokes a concentration-dependent calcium response and the maximum calcium response with an EC₅₀ value of 16 μM in a subset of cells of cultured mouse DRG neurons and excites TRPA1 in rodent sensory neurons^[3].
Dacarbazine citrate (1 mg/kg, i.p.; 1, 3, 5 and 7 days for chronic pain or 1 mg/kg, i.p. for acute treatment) induces mechanical and cold allodynia in mice^[3].
Dacarbazine citrate-induced nociception can be reduced by TRPA1-deficient mice and antisense oligonucleotide for the TRPA1 receptor^[3].
Dacarbazine citrate-induced chronic nociception can be reduced by selective TRPA1 receptor antagonists and antioxidants^[3].
Dacarbazine citrate-induced nociception can be resisted by RPA1 antagonist or an antioxidant in a tumor-associated cancer pain model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

374.31

C₁₂H₁₈N₆O₈

64038-56-8

O=C(C1=C(/N=N/N(C)C)NC=N1)N.O=C(CC(C(O)=O)(O)CC(O)=O)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Abdullah A Al-Badr, et al. Dacarbazine. Profiles Drug Subst Excip Relat Methodol  [Content Brief]

  [2]. J M Rojo, et al. Inhibition of T and B lymphoblastic response by mithramycin, dacarbazine, prospidium chloride and peptichemio. Chemotherapy. 1983;29(5):345-51.  [Content Brief]

  [3]. Int J Cancer, et al. Dacarbazine alone or associated with melanoma-bearing cancer pain model induces painful hypersensitivity by TRPA1 activation in mice. Int J Cancer. 2020 May 15;146(10):2797-2809.  [Content Brief]